Research overview based on the cited scientific literature.

• Goal: Support body composition improvements through combined lipolytic and GH-stimulating mechanisms[4][5].

• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Proper storage preserves peptide quality.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days per CDC/USP guidelines[6].
• Allow vials to reach room temperature before opening to reduce condensation uptake.

This blend combines three complementary peptides with distinct mechanisms:
• AOD-9604 is a modified C-terminal fragment of human growth hormone (amino acids 177–191) that retains the lipolytic and anti-lipogenic properties of GH without stimulating IGF-1 or affecting glucose metabolism[1][7].
• CJC-1295 is a long-acting GHRH analog that produces sustained elevations in growth hormone and IGF-1 levels[2], supporting anabolic processes and fat metabolism.
• Ipamorelin is a selective ghrelin mimetic that stimulates pulsatile GH secretion without significantly increasing ACTH or cortisol[3], offering a cleaner GH release profile.
Together, these peptides work synergistically to enhance endogenous GH pulsatility and promote favorable changes in body composition similar to exogenous GH therapy[4][5].

Observations from preclinical and clinical literature.
Potential Benefits
• Supports reduction in fat mass and enhancement of lipolysis[1][5].
• May promote lean mass gains through sustained GH and IGF-1 elevation[2][4].
• Selective GH release without significant cortisol or prolactin increases[3].
• AOD-9604 shows a placebo-like safety profile in human studies[7][8].
Possible Side Effects
• Mild injection-site reactions (redness, itching) with subcutaneous administration.
• Transient flushing or warmth following injection.
• Occasional headache or lightheadedness during initial use.
• Water retention (typically mild) with sustained GH elevation.